A phase I study of ADI-001 in patients with Anti-neutrophil-cytoplasmic-antibody-associated-vasculitis
Latest Information Update: 23 Sep 2024
At a glance
- Drugs ADI-001 (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
- 19 Sep 2024 According to an Adicet media release, initial clinical data expected in the first half of 2025.
- 13 Sep 2024 New trial record
- 10 Sep 2024 According to an Adicet media release, the company to initiate this trial by year-end. Clinical updates from this are expected in the first half of 2025.